Regeneron Pharmaceuticals (REGN) Gross Profit (2009 - 2026)

Regeneron Pharmaceuticals' Gross Profit history runs 18 years deep, the most recent figure standing at $3.3 billion for Q1 2026.

• On a quarterly basis, Gross Profit rose 16.94% year-over-year to $3.3 billion in Q1 2026; TTM through Mar 2026 was $13.9 billion, a 7.48% increase from a year earlier, with the FY2025 full-year figure at $13.4 billion, up 2.05% from the prior year.
• Gross Profit slipped to $3.3 billion in Q1 2026 per REGN's latest filing, from $3.7 billion in the prior quarter.
• Across five years, Gross Profit topped out at $3.7 billion in Q4 2025 and bottomed at -$178.0 million in Q4 2022.
• The 5-year median for Gross Profit is $3.1 billion (2023), against an average of $2.8 billion.
• Across the five-year window, Gross Profit tumbled 106.71% in 2022 and jumped 1977.75% in 2023, its largest moves.
• Year by year, Gross Profit stood at -$178.0 million in 2022, then jumped by 1884.1% to $3.2 billion in 2023, then climbed by 5.38% to $3.3 billion in 2024, then gained by 11.95% to $3.7 billion in 2025, then slipped by 11.67% to $3.3 billion in 2026.
• Per Business Quant, the three latest REGN Gross Profit figures stand at $3.3 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.5 billion (Q3 2025).